NetScientific plc (LON:NSCI) chief executive and chairman Francois Martelet hailed recent news from portfolio company Vortex Biosciences as a “very important” milestone.
Vortex has been awarded a CE Mark for its circulating tumour cell (CTC) capture system and has registered a Class I medical device with the US FDA (Food and Drug Administration).
It means moving the selling of the VTX-1 Liquid Biopsy System closer in Europe and the USA – firstly for research use only.
Martelet said it was an exciting validation of the technology, which offers a high level of purity and collection efficiency against other methods of cell capture.
“Most patients don’t die because of their tumours. Most patients die because of circulating tumour cells, which down the road, lead to metastasis,” he highlighted.
Story by ProactiveInvestors